EUCTR2005-000093-50-ES进行中（未招募）1 期
A Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Glimepiride Alone or in Combination with Metformin - MK-0431 Add-on to Glimepiride Study
Merck Sharp and Dohme de España0 个研究点目标入组 360 人开始时间: 2006年5月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •a. Patient has type 2 diabetes mellitus (T2DM).
- •b. Patient is =18 and =75 years of age.
- •d. Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period.
- •f. Patient meets one of the following criteria as indicated by a yes” answer to one of the following:
- •1) Patient is currently on glimepiride (at a dose of at least 4 mg/day) alone or in combination with metformin (at a dose of at least 1500 mg/day) for =10 weeks and has a Screening Visit/Visit 1 HbA1c =7.5% and =10.5%.
- •Patient is in 1 of the following categories (2-5) and based upon review of the patient’s current diet, medical regimen, and Screening Visit/Visit 1
- •HbA1c, patient is considered by the investigator to be likely to meet Visit 3 inclusion criterion of HbA1c =7.5% and =10.5% after a dose stable period on glimepiride monotherapy (at a dose of at least 4 mg/day) alone or in combination with metformin (at a dose of at least 1500 mg/day).
- •2) Patient is not on any antihyperglycemic medication and has a Screening Visit/Visit 1 HbA1c = 9%.
- •3) Patient is currently on glimepiride at a dose of less than 4 mg/day or is on any other sulfonylurea agent in monotherapy and has a Screening Visit/Visit 1 HbA1c =7.5%.
- •4) Patient is currently on monotherapy with any other oral antihyperglycemic agent (e.g., metformin, an alpha-glucosidase inhibitor, or a PPAR? agent [rosiglitazone or pioglitazone]) and has a Screening Visit/Visit 1 HbA1c =7.5 %.
- •5) Patient is currently on oral combination antihyperglycemic agent therapy and has a Screening Visit/Visit 1 HbA1c = 6.5 and = 10.5%.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a. Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis, or required insulin within the prior 8 weeks.
- •f. Patient has a hypersensitivity to the use of glimepiride, sulfonylurea agents, or pioglitazone or according to the label of the country of the investigational site, has any contraindication to the use of these medications or that limits the allowed doses to below those required by the protocol.
- •g. Patient has a hypersensitivity to metformin and will be on metformin during the study.
- •h. Patient has an ALT or AST >2.0-fold the Upper Limit of Normal (ULN). Note: Patients whose serum ALT or AST exceeds this limit may be retested one time if the investigator does not believe the value reflects the patient’s clinical status.
- •i. Patient is on and will be on metformin during the study and serum creatinine =1.4 mg/dL (123.8 µmol/L) in men and =1.3 mg/dL (114.9 µmol/L) in women or estimated creatinine clearance (using Cockcroft-Gault formula) <60 mL/min. Note: Patients whose serum creatinine exceeds this limit may be retested one time if the investigator does not believe the value reflects the patient’s clinical status.
- •Patient is not on or will not be on metformin during the study and patient’s renal function is reflected below as indicated by a yes” answer to one of the following:
- •1) Patient is a male =65 years of age and serum creatinine >2.0 mg/dL (176.8 µmol/L).
- •2) Patient is a male >65 years of age and serum creatinine >1.7 mg/dL (150.3 µmol/L).
- •3) Patient is a female =65 years of age and serum creatinine >1.7 mg/dL (150.3 µmol/L).
- •4) Patient is a female >65 years of age and serum creatinine >1.4 mg/dL (123.8 µmol/L).
- •5) Creatinine clearance is <45 mL/min.
- •Note: Patients whose serum creatinine exceeds this limit may be retested one time if the investigator does not believe the value reflects the patient’s clinical status.
- •j. Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months or has any of the following disorders within the past 6 months:
- •· Acute coronary syndrome (e.g., MI or unstable angina).
- •· Coronary artery intervention (e.g., CABG or PTCA).
- •· Stroke or transient ischemic neurological disorder.
- •k. Patient has congestive heart failure requiring pharmacological therapy or NYHA Class II, III or IV congestive heart failure.
- •l. Patient is HIV positive (as assessed by medical history).
- •m. Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia).
- •n. Patient has cirrhosis or active liver disease (other than fatty liver) or active nephropathy (i.e., nephrotic syndrome or glomerulonephritis) or chronic progressive neuromuscular disorder (e.g., multiple sclerosis or polymyositis) or any other condition or therapy which, in the opinion of the investigator or Merck medical monitor, might pose a risk to the patient or make participation not in the patient’s best interest.
- •o. Patient has a history of malignancy.
- •p. Patient has a history of
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BMS-986165 in Adolescent Subjects with Moderate to Severe Plaque PsoriasisEUCTR2018-001926-25-Outside-EU/EEABristol-Myers Squibb International Corporation
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Glimepiride Alone or in Combination with Metformin - MK-0431 Add-on to Glimepiride StudyMedDRA version: 7.0Level: LLTClassification code 10045242Type 2 Diabetes MellitusEUCTR2005-000093-50-SEMerck Sharp & Dohme (Sweden) AB360
招募中
1 期
A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety ofDeucravacitinib (BMS-986165) in Pediatric Subjects with Moderate toSevere Plaque PsoriasisModerate to Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code: 10071117Term: Plaque psoriasis Class: 10040785CTIS2022-502519-13-00Bristol Myers Squibb International Corporation155
进行中（未招募）
1 期
A study to compare the safety and effectiveness of a quadruple drug regimen (VX-222, telaprevir, peginterferon alfa-2a and ribavirin) to a triple drug regimen (placebo, telaprevir, peginterferon alfa-2a and ribavirin) in treating chronic hepatitis C virus in subjects with cirrhosis who are treatment naive or nonresponders and relapsers to previous Peg-IFN/Ribavirin therapy.Chronic Hepatitis C VirusMedDRA version: 20.1 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestationsEUCTR2011-004150-26-GBVertex Pharmaceuticals92
进行中（未招募）
1 期
A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects with Moderate to Severe Plaque PsoriasisModerate to Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2019-004879-39-PLBristol-Myers Squibb International Corporation153